Akero Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
719
across all filing types
Latest filing
2026-02-17
Major Shareholding Noti…
Country
US
United States of America
Listing
US
AKRO
Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-13 | English | |
| SCHEDULE 13G/A Filing | 2026-02-10 | English | |
| 15-12G | 2025-12-19 | English | |
| Delisting Announcement 2025 | 2025-12-09 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 31561392 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31561364 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31561429 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 31561437 | SCHEDULE 13G/A Filing | 2026-02-10 | English | ||
|
2025
11 filings
| |||||
| 13120288 | 15-12G | 2025-12-19 | English | ||
| 13120289 | Delisting Announcement 2025 | 2025-12-09 | English | ||
| 13120292 | 4 | 2025-12-09 | English | ||
| 13120291 | 4 | 2025-12-09 | English | ||
| 13120293 | 4 | 2025-12-09 | English | ||
| 13120294 | 4 | 2025-12-09 | English | ||
| 13120295 | 4 | 2025-12-09 | English | ||
| 13120296 | 4 | 2025-12-09 | English | ||
| 13120297 | 4 | 2025-12-09 | English | ||
| 13120298 | 4 | 2025-12-09 | English | ||
| 13120299 | 4 | 2025-12-09 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
EMBRACING FUTURE HOLDINGS LIMITED
Precision medicine medtech developing diagnostic solutions …
|
8YY | SG | Professional, scientific and te… |
|
EMYRIA LIMITED
Clinical-stage biotech developing mental health and neurolo…
|
EMD | AU | Professional, scientific and te… |
|
ENERGENESIS
Develops small molecule drugs for cellular energy regulatio…
|
6657 | TW | Professional, scientific and te… |
|
Enertopia
Energy solutions company developing patented green technolo…
|
ENRT | CA | Professional, scientific and te… |
|
E-Novia
A venture studio and consultancy that transforms Physical A…
|
E9IA | IT | Professional, scientific and te… |
|
Ensysce Biosciences, Inc.
Clinical-stage pharma firm developing abuse-deterrent drugs…
|
ENSC | US | Professional, scientific and te… |
|
Entheon Biomedical Corp.
Developing proprietary psychedelic medicines, specifically …
|
ENBI | CA | Professional, scientific and te… |
|
ENTROPY NEURODYNAMICS LIMITED
Develops computational tools and entropy-based metrics to a…
|
ENP | AU | Professional, scientific and te… |
|
Enveric Biosciences, Inc.
Develops novel small-molecule therapeutics for neuropsychia…
|
ENVB | US | Professional, scientific and te… |
|
ENVIRONMENTAL CLEAN TECHNOLOGIES LIMITED.
Develops low-emission technologies for energy, steelmaking,…
|
ECT | AU | Professional, scientific and te… |
Akero Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31200/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31200 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31200 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31200 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31200}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Akero Therapeutics, Inc. (id: 31200)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.